ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

Tamoxifen Trial Enrolls 19% Of Women Needed, Fisher Reports To NCAB

October 16, 1992

The Impact of Triple Calamities: Flat Funding, the End of ARRA, and a Dramatic Loss of Purchasing Power

October 31, 2014

ACS Reorganization Plans, Policy Changes Discussed By Board

November 29, 1991

In Brief: Upton Says Delaney Clause Is Needed: CPSC Drops Effort To Set Policy On Carcinogens

May 4, 1979

Concepts For Education Initiatives In Breast Ca Approved As RFA

July 9, 1993

In Brief: Rogers On AHF Board; GAO Says Legislation May Needed For Hospice Reimbursement

March 23, 1979